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Bone marrow stromal cells [BMSCs; also known as mesenchymal
stem cells (MSCs)] effectively suppress inﬂammatory responses in
acute graft-versus-host disease in humans and in a number of
disease models in mice. Many of the studies concluded that BMSCdriven immunomodulation is mediated by the suppression of proinﬂammatory Th1 responses while rebalancing the Th1/Th2 ratio
toward Th2. In this study, using a ragweed induced mouse asthma
model, we studied if BMSCs could be beneﬁcial in an allergic, Th2dominant environment. When BMSCs were injected i.v. at the time
of the antigen challenge, they protected the animals from the
majority of asthma-speciﬁc pathological changes, including inhibition of eosinophil inﬁltration and excess mucus production in the
lung, decreased levels of Th2 cytokines (IL-4, IL-5, and IL-13) in
bronchial lavage, and lowered serum levels of Th2 immunoglobulins (IgG1 and IgE). To explore the mechanism of the effect we
used BMSCs isolated from a variety of knockout mice, performed
in vivo blocking of cytokines and studied the effect of asthmatic
serum and bronchoalveolar lavage from ragweed challenged
animals on the BMSCs in vitro. Our results suggest that IL-4 and/
or IL-13 activate the STAT6 pathway in the BMSCs resulting in an
increase of their TGF-β production, which seems to mediate the
beneﬁcial effect, either alone, or together with regulatory T cells,
some of which might be recruited by the BMSCs. These data suggest that, in addition to focusing on graft-versus-host disease and
autoimmune diseases, allergic conditions—speciﬁcally therapy
resistant asthma—might also be a likely target of the recently
discovered cellular therapy approach using BMSCs.
allergy

| cellular therapy | immunomodulation | mesenchymal stem cell

A

sthma is a chronic inﬂammatory airway disease affecting 16
million people in the United States alone and more than 300
million worldwide (1). It can range from a mild, intermittent
disease to one that is severe, persistent, and difﬁcult to treat (i.e.,
therapy-resistant) (2). Asthma-related deaths are uncommon,
but they appear to be increasing; currently there are approximately 5,000 deaths per year in the United States and 100,000
throughout the world (3). New treatments are needed for therapy-resistant, severe cases.
Bone marrow stromal cells (BMSCs) have recently been shown
to suppress harmful immune responses in patients with acute graftversus-host disease (4, 5) and in several animal models of allogeneic
rejection (6–8), a variety of autoimmune diseases (9–11), and lung
injury (12–15). The authors of many of these studies concluded that
BMSC-driven immunosuppression results from a shift in Th1/Th2
balance (8, 16, 17). During BMSC treatment, Th1 responses appear
to be decreasing while Th2 responses begin to dominate. In animals
with established allergies, Th2 responses are already dominant, and
we wondered how BMSCs would react to such an environment. In
this study we thus examined the effect of BMSCs on Th2-driven
allergic reactions in a mouse model of asthma (18, 19).
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Results
Lung Pathology. Following ragweed (RW) challenge (for timing of

the events see Fig. 1), microscopic examination of the lungs showed
minimal or no inﬂammation in mice sensitized with PBS solution
and alum but no RW (Fig. 2A). Conversely, RW-sensitized mice
showed extensive inﬂammation with eosinophil and lymphocyte
invasion and severe perivascular and peribronchial cufﬁng (Fig. 2B).
Mice that were challenged with RW but treated with i.v. injections of
BMSCs had signiﬁcantly less lung pathology: few inﬂammatory cell
inﬁltrates were observed (Fig. 2C). Although no abnormal mucusﬁlled cells were observed in controls as deﬁned by histological
staining using PAS (Fig. 2D), the amount of stainable mucus in the
airways was visibly increased following RW challenge (Fig. 2E).
BMSC treatment reduced the amount of mucus to near control
levels (Fig. 2F). In addition to improved lung scores (Fig. 3A), we
also observed a signiﬁcant decrease in both total inﬂammatory cell
numbers and eosinophils in the bronchoalveolar lavage (BAL) ﬂuid
(Fig. 3 B and C).
Cytokine Response. RW-challenged mice showed increased levels of
IL-4, IL-13, and IL-5 in BAL, all characteristic Th2 cytokines that
highlight allergic inﬂammation. IL-4 and IL-13 levels were signiﬁcantly reduced when the animals were treated with i.v. BMSCs
(Fig. 3 D–F).
Ig Response. RW sensitization and subsequent antigen challenge is

known to affect Th2-speciﬁc Ig concentrations in blood (19).
Indeed, we found that both IgG1 and IgE serum levels were signiﬁcantly increased following RW application, whereas IgG2a did
not change. BMSC treatment resulted in a signiﬁcant decrease of
RW induced elevation of IgG1 and IgE concentrations (Fig. 3 G–I).
Use of Allogeneic BMSCs or Skin Fibroblasts Instead of Syngeneic
BMSCs. In a few groups of mice, we determined whether there was a

difference in effect when we use allogeneic BMSCs prepared from
Balb/C mice or syngeneic C57BL/6J dermal ﬁbroblasts instead of
syngeneic (C57/BL6) BMSCs. We measured total cell numbers
and the number of eosinophils (Fig. 4 A and B) as well as IL-4 and
IL-13 levels (Fig. 4 C and D) from BAL and immunoglobulins from
serum (Fig. 4 E–G). We found that there was no signiﬁcant dif-
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Fig. 1.

Timeline of the experiments showing the days of the interventions.

Searching for Mechanism of Action. One hour after i.v. injection of
BMSCs on d 14, the cells were found exclusively in the lung
whereas virtually no cells were seen in other organs as demonstrated by bioluminescence measurements using luciferase
expressing stromal cells (Fig. 5A). To determine if the inﬂammatory environment seen in asthma could inﬂuence homing to
and/or survival of BMSCs in the lung, we injected luciferaseexpressing cells into animals on d 14, immediately after intraairway application of PBS solution or RW. Comparing emitted
luminescence at different time points we assessed the number of
stromal cells still present in the lungs. At 1, 12, and 24 h, the
number of BMSCs in control and asthmatic animals were comparable, whereas at 36 h—and more evidently after 48 h—we
detected considerably more BMSCs in the asthmatic lungs (Fig.
5A). To follow up on this observation, we injected Q-dot–labeled
BMSCs into control and RW-challenged animals and isolated

Fig. 2. Histological images of airways stained with PAS to show the mucinproducing goblet cells (dark red in the lumen). Low-magniﬁcation images
depict a control lung (A), a lung following RW challenge with no treatment (B),
and a lung with BMSC treatment (C). Note the signiﬁcant increase in lymphocytic inﬁltrates (arrows) in B and their decrease in C. The high magniﬁcation images of the airways show a normal bronchus in D, a bronchus from RWchallenged mouse with mucus buildup (arrows) in the luminal surface (E), and a
treated mouse with less mucus in F. (Scale bar, 250 μm in A–C and 50 μm in D–F.)
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Fig. 3. Evaluation of the effect of BMSC treatment on the different
parameters of RW-induced asthma. Mice treated with BMSCs showed a
signiﬁcant reduction in lung histology scores (A), total number of BAL cells
(B), relative ratio of BAL eosinophils (C), and levels of allergy-speciﬁc Th2
cytokines IL-4 (D), IL-13 (E), and IL5 (F) in BAL. From the sera of challenged
mice we measured Ig concentrations, and in the BMSC-treated group we
found a signiﬁcant decrease in the level of Th2-speciﬁc Ig concentrations
IgG1 (G) and IgE (H), whereas there was no change in the level of IgG2a (I).
There were four to eight mice per group. *P < 0.05, **P < 0.01, and ***P <
0.001 in all graphs.

the Q-dot–positive BMSCs from the protease-digested lung cell
suspensions using FACS. At 6, 12, and 24 h after injection, the
number of Q-dot–positive cells did not differ between the two
groups. After 36 h, however, we detected a signiﬁcant increase in
the number of BMSCs retained in the asthmatic lungs, and this
difference remained detectable at 48, 72, and 96 h after BMSC
injection (Fig. 5 B and C). These observations suggest that the
developing allergic environment is capable to attract and retain
more BMSCs than unaffected lungs, indicating that asthmatic
lungs are likely to secrete factors that affect BMSC homing and
survival. We next continued to explore the nature of such factors.
Among the number of cytokines known to suppress allergic
responses the antiinﬂammatory actions of IL-10, TGFβ, and IFN-γ
are especially well established. To determine whether any of these
factors contributes to the beneﬁcial effect of BMSCs, we ﬁrst
examined their levels in BAL ﬂuid. There was a signiﬁcant increase
in the level of TGF-β in BAL ﬂuid collected from BMSC-treated
versus untreated mice, but no change in IFN-γ or IL-10 levels
(Fig. 6 A–C). As TGF-β was increased in BAL ﬂuid, and BMSCs
are reported to be able to secrete TGF-β (20), we next asked
whether serum or BAL ﬂuid from RW-challenged mice could
affect TGF-β production by BMSCs in vitro. TGF-β increased
in the medium when BMSCs were cultured in the presence of RWchallenged serum or BAL, suggesting that allergy-speciﬁc microenvironment (i.e., serum or BAL) is capable of modulating
immunoregulatory functions of BMSCs. It has been reported that
stimulation of certain immune cells through the IL-4R pathway
results in up-regulated TGF-β expression (32). To ﬁnd out if
enhanced TGF-β production by BMSCs in the presence of allergic
PNAS | March 23, 2010 | vol. 107 | no. 12 | 5653
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ference between syngeneic versus allogeneic BMSCs (i.e., both
were equally effective), and skin ﬁbroblasts had only partial effect.
Although the number of total cells in BAL was reduced following
ﬁbroblast treatment, the number of eosinophils was not different
from the untreated group. Fibroblasts behaved similarly to BMSCs
in regulating cytokine levels, but they had no effect on serum IgE
concentrations. Interestingly, IgG2a levels were highly increased
following ﬁbroblast administration—an effect that we never
observed using BMSCs.
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Fig. 4. Assessing the effect of allogeneic BMSCs or syngeneic skin ﬁbroblasts on RW-induced asthma. Allogeneic BMSCs exhibit a similar inhibitory effect as
syngeneic BMSCs on the total number of BAL cells (A), relative ratio of eosinophils (B), BAL inﬂammatory cytokines IL-4 (C) and IL-13 (D), and serum
immunoglobulins IgG1 (E), IgE (F), and IgG2a (G). There were four to eight mice per group. Skin ﬁbroblasts had a partial effect on the aforementioned
parameters (see same graphs).

serum or BAL could be triggered by activation through the IL-4R,
we repeated the aforementioned experiments using IL-4R–
deﬁcient BMSCs. We found that RW-challenged serum or BAL
could not enhance TGF-β production in IL-4R–KO BMSCs,
suggesting an important role for IL-4 (Fig. 6D).
As both IL-4 and IL-13 are able to bind to IL-4R, in another
series of experiments we examined the effect of blocking (using
speciﬁc antibodies) IL-4, IL-13, or both on the TGF-β production
by BMSCs when they came in contact with RW-sensitized serum or
BAL (Fig. 6 E and F). When serum from RW challenged mice was
added to the media, IL4 neutralization alone eliminated the
increased TGF-β production but blocking IL-13 did not have this
effect (Fig. 6E). Interestingly, when BAL from RW challenged
mice was added, the BMSCs increased their TGF-β production
even when either IL-4 or IL-13 was blocked; however, blocking
both cytokines simultaneously eliminated the effect (Fig. 6F). On
the other hand, neither recombinant IL-4 or IL-13 alone or in
combination increased TGF-β production (Fig. S1), suggesting a
possible role for other factors.

When treating mice with TGF-β– and IL-10–speciﬁc neutralizing antibodies before BMSC injection, we observed that blocking
TGF-β—but not IL-10—eliminated the beneﬁcial effect of
BMSCs demonstrated by the lack of reduction in BAL total cell
numbers and eosinophil counts (Fig. 7 A and B). Furthermore, in
mice injected with TGF-β1–KO BMSCs, the beneﬁcial effect was
no longer seen: treated animals showed no reduction in BAL cell
numbers, asthma-speciﬁc BAL cytokines, or serum Th2 immunoglobulins. Importantly TGF-β1–KO cells were unable to elicit
increase in BAL TGF-β concentrations, suggesting that BMSCderived TGF-β1 is responsible for the effect (Fig. 7C).
The IL-4 receptor is known to activate the STAT6 signaling
pathway (21). To see if the IL4Ra/STAT6 pathway is indeed
necessary for the BMSCs to act beneﬁcially in an allergic environment—as suggested by the in vitro studies just described—we
injected STAT6-deﬁcient BMSCs instead of WT cells and
observed no TGF-β elevation in the BAL samples (Fig. 7C). In
accordance with this result the elimination of STAT6 also reversed

Fig. 5. After i.v. delivery of BMSCs at the time of the ﬁrst challenge, stromal cells are concentrated in the lung. Asthmatic lungs seem to retain more BMSCs
than control unchallenged lungs at 48 h after administration, demonstrated by bioluminescence detection of luciferase-expressing stromal cells. Two representative mice of three used are shown (A). To conﬁrm this observation, Q-dot–labeled BMSCs were injected at the time of the ﬁrst challenge, and lung cell
suspensions were analyzed using FACS at several time points after injection. After 6 h, the number of Q-dot–positive cells (BMSCs) are still comparable in the
two groups (each had four mice), but starting at 12 h there are signiﬁcantly more BMSCs retained in the asthmatic lungs compared with the controls at all
time points examined (B and C).
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Fig. 8. Quantiﬁcation of regulatory T cells in asthmatic lungs. With time
there is a gradual increase in the number of regulatory T cells in lungs
challenged with RW. BMSC-treated asthmatic lungs show a greater inﬂux of
T-regs starting at 36 h after challenge and further increasing up to 96 h.

the BMSC-derived attenuation of RW-induced asthma, pointing
to the importance of the IL4R/STAT6 pathway (Fig. 7 D–J).
As regulatory T cells (T-regs) are known to play a role in
alleviating asthma symptoms and TGF-β has been suggested to

Fig. 7. In vivo demonstration of mechanism of action. The beneﬁcial effect of
BMSCs on inﬂammatory changes is eliminated in the presence of TGF-β neutralizing antibodies, but spared when animals are treated with anti-IL-10 antibodies (A and B). BMSCs from TGF-β or STAT6 deﬁcient animals did not induce
TGF-β production (C ) or decrease BAL total cell numbers (D), eosinophil numbers
(E), cytokine levels (F and G), or serum immunoglobulin concentrations (H–J).

Nemeth et al.

play a role in T-reg differentiation, we wondered if the number
of T-regs in the lung tissue could also be affected by the BMSC
treatment in our model. Analyzing lung single cell suspensions
using FACS, we detected a steady increase in the number of
T-regs in challenged animals over time. Importantly, as early as
after 48 h, as well as after 72 and 96 h after challenge, we found
signiﬁcantly more T-regs in the BMSC-treated lungs than the
ones collected from challenged but untreated animals (Fig. 8).
Discussion
Asthma is an inﬂammatory disease of the airways. In asthma, the
lungs are invaded by a variety of inﬂammatory cells, including
eosinophils and lymphocytes. These cells, in addition to resident
mast cells, secrete cytokines and chemokines that trigger constriction of the bronchi and secretion of mucus.
The current working hypothesis is that asthma is caused by an
abnormal shift in the Th1/Th2 balance in favor of Th2 cells and
the production of IL-4, IL-5, and IL-13. Through these mediators,
Th2 lymphocytes are thought to recruit additional effector cells to
the lungs, and the cells recruited promote allergic inﬂammatory
events (22). BMSCs have been shown to have useful effects in a
number of diseases and disease models. In the majority of these
disorders, however, the T cell balance is shifted toward Th1
dominance. As BMSCs seem to “normalize” immune responses
and reestablish the physiological balance in a variety of autoimmune and infectious diseases (23–27), we wondered whether
these cells might also be able to tip the balance back to normal in
an allergic environment with already-established Th2 dominance.
The rebalancing act would require that the cells detect an
imbalance and then take appropriate measures to correct it.
Our initial experiments showed that injecting BMSCs on d 14,
when ﬁrst challenging the sensitized animals signiﬁcantly
improved lung pathology, such as total cell number in BAL;
number of eosinophils in BAL and lung scores. Using luciferaseexpressing or Q-dot–labeled BMSCs, we demonstrated that
lungs are the primary site of BMSC accumulation following i.v.
injection, conﬁrming the known phenomenon of cell trapping in
the pulmonary microvasculature that is partially related to cell
size (28, 29). However, using Q-dot–labeled BMSCs we found
signiﬁcantly more BMSCs retained in the lungs when RWinduced allergic inﬂammation was present compared with the
unchallenged state—a tendency also suggested by the bioluminescent measurements. As in our model, the primary site of
pathologic processes is the lung itself, and the enhanced presence of BMSCs could deliver a concentrated effort to modulate
pathological immune responses.
PNAS | March 23, 2010 | vol. 107 | no. 12 | 5655
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Fig. 6. Studying the mechanism of BMSC effect. In BAL BMSC treatment
resulted in elevated TGF-β levels (A). IFN-γ (B) and IL-10 (C) did not change.
Serum or BAL from RW challenged mice induced BMSCs to producemore
TGF-β in vitro, but this effect was eliminated when BMSCs lacked IL-4Ra (D).
Using neutralizing antibodies for IL-4 or IL-13 suggested both cytokines are
involved in stimulating BMSC’s TGF-β production when cocultured with
serum (E) or BAL (F) from RW challenged mice.

Fig. 9. Schematic drawing shows the mechanism of effect based on data of
the present study. BMSCs “sense” the allergic environment, and as a result of
the increased levels of IL-4/IL-13, they respond by producing higher amounts
of TGF-β that, either alone or by recruiting regulatory T cells, will ultimately
lead to a decrease of lung eosinophil inﬁltration, as well as allergy-speciﬁc
cytokine and Ig production.

IL-10 and TGF-β, two well characterized antiinﬂammatory
cytokines, and IFN-γ, a key Th1 cytokine capable of downregulating Th2-mediated pathological responses, are all thought
to be capable of suppressing asthma (22, 30). As IL-10 has been
shown to play a signiﬁcant role in the beneﬁcial effect of BMSCs in
sepsis (27), we ﬁrst measured cytokines in serum and BAL in the
treated versus untreated RW-challenged mice. We found no
change in IL-10 or IFN-γ levels, but there was a signiﬁcant increase
in the level of TGF-β, suggesting a different mechanism of action
than what was found in a septic environment. We then demonstrated the importance of TGF-β in vivo by treating the mice with
TGF-β–speciﬁc neutralizing antibodies before BMSC injection.
Blocking TGF-β—but not IL-10—eliminated the beneﬁcial effect
of BMSC treatment. Next we looked for a possible source of
TGF-β. BMSCs themselves are capable of secreting TGF-β (31),
which has been implicated as one of the possible mediators of the
BMSCs’ immunosuppressive effect. We thus repeated the
experiment injecting BMSCs derived from TGF-β1–KO mice and
found no beneﬁcial effect, suggesting that the BMSC-derived
TGF-β is critical in suppressing the allergic responses. As TGF-β
synthesis can be enhanced through IL-4R in some immune cells
(32), we wondered if it is the IL-4 and IL-13 that “turns on” the
BMSCs to make TGF-β. We ﬁrst used BMSCs from mice lacking
the IL-4R (which is used by both IL-4 and IL-13) and found that
RW-challenged serum or BAL could no longer elicit increased
TGF-β production in these cells in vitro. In another set of
experiments using neutralizing antibodies against IL-4 or IL-13,
we could further demonstrate the importance of the IL4R. As the
IL-4R is known to activate the STAT6 pathway (21), we wanted to
conﬁrm our results by using BMSCs that genetically lacked
STAT6. As expected, STAT6-KO BMSCs were ineffective in
alleviating asthma pathology and could not trigger TGF-β elevation in the BAL ﬂuids either. Based on these data, we suggest
that IL-4 and/or IL-13 bind to IL-4R receptors on BMSCs activating the STAT6 pathway. This, in turn, drives the cells to produce increased amounts of TGF-β. When this TGF-β is released
from the BMSCs in the allergic (i.e., Th2-dominant) environment,
TGF-β receptor activation on immune cells could result in a
decrease in IL-4 production (33) and ultimately leads to a shift
back toward immunological equilibrium (Fig. 9). Surprisingly,
neither recombinant IL-4 nor IL-13 alone or in combination was
able to elicit the elevation of TGF-β by BMSCs seen with RWconditioned BAL ﬂuid or blood serum in vitro. This indicates that
activation of the IL-4R/STAT6 pathway is necessary but not suf5656 | www.pnas.org/cgi/doi/10.1073/pnas.0910720107

ﬁcient to cause TGF-β up-regulation in BMSCs. In addition to IL4 or IL-13, there must be other important factors in vivo (present in
BAL ﬂuid or serum) that contribute to the production and subsequent release of TGF-β by BMSCs.
We also demonstrated that BMSC-treated asthmatic animals
recruit signiﬁcantly more regulatory T cells to the lungs than
untreated mice. In animal models of allergic airways disease,
T-regs can suppress established airway inﬂammation and airway
hyperresponsiveness (34). Regulatory T cells are thought to suppress infection/inﬂammation by secreting antiinﬂammatory molecules (e.g., IL-10, TGF-β) (35, 36). It is possible that BMSCs work
together with regulatory T cells to suppress harmful allergic
responses in our model. BMSCs could initiate the suppressive
process by secreting TGF-β to block the proinﬂammatory Th2
responses and at the same time induce the differentiation and help
the survival of regulatory T cells (30) that will then continue to
improve asthma pathology after the BMSCs disappear.
It is worth mentioning that dermal ﬁbroblasts—cells frequently
used as control cells in studies of BMSCs—had beneﬁcial effects in
the model that we used when injected intravenously. The effect of
the ﬁbroblasts was not as strong as that of BMSCs. This suggests,
however, that ﬁbroblast-like cells, whether derived from the bone
marrow or other organs (including skin dermis), may also have
some immunomodulatory properties (37).
In the present study we demonstrated that i.v. injected BMSCs
are capable of suppressing Th2-driven allergic responses. It appears
that IL-4 and/or IL-13 induce production and secretion of TGF-β by
the BMSCs, which in turn effectively suppresses allergy speciﬁc
pathological changes in the asthma model we studied. These data
provide another example of the ability of BMSCs to “sense” their
immunological environment and respond accordingly. It is hard to
imagine a drug or combination of drugs that could act this way, and
further work should be done to determine whether the cells could be
used to treat patients with therapy-resistant asthma.
Methods
Mice. C57BL/6J or Balb/C mice (6 to 8 weeks old) were obtained from Taconic
Farms. IL-4Rα–KO and STAT6-KO animals were purchased from Jackson
Laboratories. TGF-β1–KO mice have previously been produced and characterized (38). The animals were housed and maintained in the National
Institute of Allergy and Infectious Diseases or National Institute of Dental
and Craniofacial Research animal facilities. All studies conformed to the
principles for laboratory animal research outlined by the Animal Welfare
Act, and were approved by the National Institute of Dental and Craniofacial
Research and/or National Institute of Allergy and Infectious Diseases Animal
Care and Use Committee. The groups for in vivo studies contained four to 10
mice, and each experiment was repeated two to three times.
Antigen Challenge. To elicit a bronchial allergic response, RW sensitization and
challenge were used (18, 19). C57BL/6J mice were sensitized on d 0 and 5
with 200 μL i.p. injections of 50 μg RW extract (Greer Laboratories), emulsiﬁed in an equal volume (100 μL/antigen injection) of alum (Pierce) as
described earlier (39). Control animals were injected i.p. with the same
amount of alum mixed with PBS solution. Subsequently, as shown in Fig. 1,
the mice were challenged on d 14 and 15 with 50 μg RW extract in PBS
solution by intratracheal and intranasal inoculation (30 μL), respectively.
Control mice received an equal volume of PBS solution administered via the
same routes. In all cases, mice were killed by anesthetizing them with ketamine (Fort Dodge Animal Health) and xylazine (Phoenix Pharmaceuticals)
100 mg/kg and 10 mg/kg, respectively, followed by exsanguination.
Histology. To assess pulmonary inﬂammation, BAL was performed 72 h after the
ﬁnal allergen challenge (as described later). Lungs were then immediately
placed in 10% neutral buffered formalin and sent to Histoserv (Germantown,
MD), where they were embedded in parafﬁn and stained. H&E was used to
evaluate cellular inﬂammation and periodic acid–Schiff (PAS) stain was used to
visualize mucus-containing goblet cells. Slides were coded and read “blind”; a
minimum of four lungs per group were given scores ranging from 0 to 2 based
on the level of peribronchial cufﬁng, perivascular cufﬁng, goblet cell hyperplasia, and interstitial inﬂammation (40).
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In Vivo Neutralization of Cytokines. IL-10– or TGF-β–neutralizing antibodies
(Clone 2A5 from Pierce Endogen or Clone 1D11 from R&D Systems, respectively) were injected intraperitoneally (10 μg/g body weight in 200 μL PBS) on
two consecutive days at the approximate time of BMSC injection (d 14
and 15).

Preparation of Lung Cell Suspension. Lungs were removed, minced into small
pieces, and incubated in RPMI medium 1640 with 1% penicillin–streptomycin
and 1% glutamine for 30 min at 37 °C 5% CO2 in the presence of collagenase
type 1 (300 U mL−1) and DNase I (50 U mL−1; Worthington Biochemicals).
After the incubation, the cell suspension was ﬁltered through a 70-μm cell
strainer and then washed with complete RPMI medium.
Data Analysis. Data are summarized as mean ± SE. Student t test or two-way
ANOVA were performed using GraphPad Prism version 4.00 for Macintosh
(GraphPad Software). The statistical signiﬁcance value was set at P < 0.05.

Measurement of Serum Antibody Isotypes. Antibody isotypes (IgG1, IgG2a, and
IgE) were assayed in sera collected 72 h after last RW challenge using ELISA kits
according to the manufacturer’s instructions (Immunology Consultants Laboratory). All samples, including standards, were assayed in duplicate.
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BAL. Immediately after the mice were exsanguinated, the lungs were cannulated with a 20-gauge i.v. catheter and gently washed once with 500 μL 1%
FBS (HyClone) in PBS solution (for cytokine analysis) or twice with 750 μL 1%
FBS in PBS solution (for analysis of cellular inﬁltration). Samples for cytokine
analysis were stored at −80°C. Samples for cellular analysis were spun onto
glass slides in a cytospin instrument (Thermo-Shandon) and stained with
Kwik-Diff for differential cell analysis (Thermo-Shandon). A fraction was
used to determine total cell counts.

